About: Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.10 (+2.50%)
INTSNASDAQIntensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc. Common stock share price
INTS price activity
Last Price
$4.100
Change (24hr)
0.10 USD (2.50%)
Volume
4.44K
Volume (4w avg)
-
Open
$3.99
Day Range
$3.99 - $4.11
Previous Close
$4.00
Last Trade
04 Sep, 8:00 pm GMT+0
Delayed
04 Sep, 8:00 pm GMT+0
INTS price performance
Delayed
04 Sep, 8:00 pm GMT+0
INTS Market Signals